AbbVie's Cancer Drug Venetoclax Falls Short In Phase 3 Combination Trial For Myelodysplastic Syndromes

AbbVie Inc (NYSE:ABBV) on Monday announced an update from the global Phase 3 VERONA trial evaluating venetoclax in combination with azacitidine for newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS).

MDS is a group of cancers in which the bone marrow doesn’t produce enough healthy blood cells.

The primary outcome measure is overall survival (OS). Key secondary outcome measures include a modified overall response (mOR) and complete remission (CR).

Also Read: AbbVie Scores FDA Approval For Its Blockbuster Drug Rinvoq To Treat Type Of Arthritis

The trial did not meet the primary endpoint of overall survival (OS) with a hazard ratio (HR) of 0.908; stratified log-rank, p=0.3772. No new safety signals were observed.

Results from the VERONA trial will be available in a future medical congress and/or publication.

The treating physician will inform any patients who received venetoclax in combination with azacitidine through participation in the MDS clinical trials. 

These ...